Compare AZO & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZO | ARGX |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5B | 52.6B |
| IPO Year | 1991 | 2017 |
| Metric | AZO | ARGX |
|---|---|---|
| Price | $3,442.89 | $845.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 19 |
| Target Price | ★ $4,329.42 | $971.89 |
| AVG Volume (30 Days) | 176.8K | ★ 308.4K |
| Earning Date | 12-09-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 143.45 | 23.27 |
| Revenue | ★ $19,287,706,000.00 | $3,683,281,000.00 |
| Revenue This Year | $9.58 | $91.22 |
| Revenue Next Year | $7.37 | $36.36 |
| P/E Ratio | ★ $24.09 | $33.78 |
| Revenue Growth | 3.81 | ★ 92.98 |
| 52 Week Low | $3,162.00 | $510.06 |
| 52 Week High | $4,388.11 | $934.62 |
| Indicator | AZO | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 38.87 |
| Support Level | $3,344.04 | $843.03 |
| Resistance Level | $3,486.20 | $858.80 |
| Average True Range (ATR) | 82.40 | 15.73 |
| MACD | -1.86 | -5.97 |
| Stochastic Oscillator | 20.45 | 20.01 |
AutoZone operates as a leading retailer of aftermarket automotive parts in the United States. The firm operates more than 6,500 stores domestically, serving the do-it-yourself and commercial (do-it-for-me) end markets. Through its vast store footprint and distribution network, AutoZone manages a wide array of stock-keeping units applicable to numerous vehicle makes and models, providing its consumers with ample product availability. The firm drives traffic by providing superior and convenient customer service as AutoZone's team of knowledgeable staff assists consumers with diagnosing a vehicle's problem, selecting the necessary part for replacement, and occasionally, installation. The company also operates internationally, with more than 800 stores in Mexico and over 100 in Brazil.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.